Trial Implementation

Risks & contraindications

Background

Other

Highlighted claims

• Recruitment began in March 2022, ended on 31 December 2024, and trial completion is expected in July 2026. — A multicentred two-arm parallel single-blind superiority randomised controlled trial comparing psychological and emotional stabilisation with eye movement desensitisation and reprocessing and treatment-as-usual to treatment-as-usual with adults with intellectual disabilities who have post-traumatic
• The COVID-19 pandemic severely disrupted the trial and delayed research resumption across sites into 2022 and early 2023. — A multicentred two-arm parallel single-blind superiority randomised controlled trial comparing psychological and emotional stabilisation with eye movement desensitisation and reprocessing and treatment-as-usual to treatment-as-usual with adults with intellectual disabilities who have post-traumatic
• Session fidelity is monitored using encrypted audio recordings and separate checklists for PES and EMDR. — A multicentred two-arm parallel single-blind superiority randomised controlled trial comparing psychological and emotional stabilisation with eye movement desensitisation and reprocessing and treatment-as-usual to treatment-as-usual with adults with intellectual disabilities who have post-traumatic
• The process evaluation follows UK Medical Research Council guidelines and assesses implementation, fidelity, adverse events, dropout reasons, and acceptability. — A multicentred two-arm parallel single-blind superiority randomised controlled trial comparing psychological and emotional stabilisation with eye movement desensitisation and reprocessing and treatment-as-usual to treatment-as-usual with adults with intellectual disabilities who have post-traumatic